Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
High-grade serous carcinoma (HGSC) of tubo-ovarian origin is a malignant neoplasm with heterogeneous morphology. This intratumour morphological heterogeneity comprises various architectural patterns and diverse cytological aspects, which often coexist within a single tumour.1 Although HGSC is characterised by a high mitotic rate and substantial nuclear pleomorphism, architecturally and/or cytologically diverse areas can cause diagnostic confusion.1 The current case illustrates that clear cell changes in HGSC can provoke ‘blunderbuss immunohistochemistry’,2 leading the pathologist astray and resulting into academic referral because of unexpected staining patterns.
A woman in her 70s underwent a bilateral salpingo-oophorectomy because of an enlarged right ovary. This ovary contained a predominantly solid and partially cystic mass, measuring 4.5×3×2.5 cm. The left ovary and both Fallopian tubes did not show any anomalies. Peritoneal carcinomatosis was not observed. Histopathological evaluation of the left ovary and both Fallopian tubes was normal. Sampling of the unilateral right ovarian mass revealed a neoplasm with prominent cytonuclear atypia, numerous mitoses (including several atypical mitotic figures) and extensive necrosis. The tumour had a mixed solid, cribriform and glandular architecture. Because of some solid clear cell areas, immunohistochemical stainings for CD117 and placental alkaline phosphatase (PLAP) had initially been performed …
Handling editor Mona El-Bahrawy.
Contributors MRVB: data collection, data analysis and writing of the first draft. DA: data collection, data analysis, reviewing and editing of the manuscript. Both authors substantially contributed to and agreed with the final version of the manuscript.
Funding MRVB received a postdoctoral mandate (grant 2019-089) from the Foundation against Cancer (Brussels, Belgium).
Competing interests None declared.
Patient consent for publication Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.